Publications
2 shownGemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Purpose The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metasta...
Frequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 2
- Citations
- 834
- Institution
- Cancer Research Center
External Links
Identifiers
- ORCID
- 0000-0001-9247-979X
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.